Search results for " progress."

showing 10 items of 1281 documents

15-prostaglandin dehydrogenase expression alone or in combination with ACSM1 defines a subgroup of the apocrine molecular subtype of breast carcinoma.

2008

Established histopathological criteria divide invasive breast carcinomas into defined groups. Ductal of no specific type and lobular are the two major subtypes accounting for around 75 and 15% of all cases, respectively. The remaining 10% include rarer types such as tubular, cribriform, mucinous, papillary, medullary, metaplastic, and apocrine breast carcinomas. Molecular profiling technologies, on the other hand, subdivide breast tumors into five subtypes, basal-like, luminal A, luminal B, normal breast tissue-like, and ERBB2-positive, that have different prognostic characteristics. An additional subclass termed "molecular apocrine" has recently been described, but these lesions did not ex…

AdultSilver StainingBreast NeoplasmsBiologyProteomicsBiochemistrySubclassAnalytical ChemistryImmunophenotypingCohort StudiesBreast cancerCoenzyme A LigasesmedicineBiomarkers TumorHumansElectrophoresis Gel Two-DimensionalNeoplasm Invasivenessskin and connective tissue diseasesMolecular BiologyAgedAged 80 and overTissue microarrayParaffin EmbeddingApocrineMiddle Agedmedicine.diseaseImmunohistochemistryApocrine GlandsPhenotypeTissue Array AnalysisImmunologyCancer researchDisease ProgressionHydroxyprostaglandin DehydrogenasesImmunohistochemistryFemaleApocrine CellBreast carcinomaMolecularcellular proteomics : MCP
researchProduct

Scheie syndrome: enzyme replacement therapy does not prevent progression of cervical myelopathy due to spinal cord compression.

2009

Hurler-Scheie syndrome is caused by alpha-l-iduronidase deficiency. Enzyme replacement therapy (ERT) can improve physical capacity and reduces organomegaly. However, the effect on bradytrophic connective tissue is limited. As intravenously administered enzyme cannot cross the blood-brain barrier, the therapy of choice for the more severe Hurler syndrome is haematopoietic stem cell transplantation (HCT). In the more attenuated Scheie syndrome, neurological impairment is less severe; therefore, ERT may be appropriate to treat these patients. Information on long-term outcome in Scheie patients undergoing ERT is scarce. We report a 38-year-old female Scheie patient who has been on ERT for 8 yea…

Adultcongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyMucopolysaccharidosis IMyelopathyIduronidaseSpinal cord compressionMucopolysaccharidosis IGeneticsmedicineHumansEnzyme Replacement TherapyHurler syndromeGenetics (clinical)business.industryHematopoietic Stem Cell Transplantationnutritional and metabolic diseasesBrainEnzyme replacement therapymedicine.diseaseSpinal cordSurgeryTransplantationmedicine.anatomical_structureCervical VertebraeDisease ProgressionFemaleScheie syndromebusinessSpinal Cord CompressionJournal of inherited metabolic disease
researchProduct

Increase in Nocturnal Blood Pressure and Progression to Microalbuminuria in Type 1 Diabetes

2002

Patients with type 1 diabetes mellitus and microalbuminuria often have elevated blood pressure while they are asleep, but it is not known whether the elevation develops concomitantly with microalbuminuria or precedes it.We monitored 75 adolescents and young adults who had had type 1 diabetes with normal urinary albumin excretion and blood pressure for more than five years. Ambulatory blood-pressure monitoring was used to assess blood pressure at the initial evaluation and about two years later, at which time all subjects had normal urinary albumin excretion. Subsequently, subjects were monitored for the development of microalbuminuria.Microalbuminuria developed in 14 subjects, whereas the o…

Adultmedicine.medical_specialtyAdolescentBlood PressureExcretionInternal medicineDiabetes mellitusmedicineAlbuminuriaHumansProspective StudiesGlycated HemoglobinType 1 diabetesProteinuriabusiness.industryAlbuminGeneral MedicineBlood Pressure Monitoring Ambulatorymedicine.diseaseCircadian RhythmDiabetes Mellitus Type 1EndocrinologyBlood pressureAmbulatoryDisease ProgressionCardiologyMicroalbuminuriamedicine.symptombusinessBiomarkersNew England Journal of Medicine
researchProduct

Effect of radiosynoviorthesis on the progression of arthropathy and haemarthrosis reduction in haemophilic patients.

2017

IntroductionRepeated haemarthrosis is widely accepted as the triggering cause of synovitis and haemophilic arthropathy. A first-line treatment of chronic synovitis is radiosynoviorthesis (RS). The aim of this study was to evaluate the RS effects on the progression of arthropathy and on a reduction in bleeding in patients with haemophilia. MethodsAn observational-retrospective study was performed. Bleeding episodes in the 12months following and in the 12months preceding RS was compared. The arthropathy was clinically and radiologically analysed by age range, joint and subject, comparing those undergoing RS (Radiosynoviorthesis Group, RSG) against those not undergoing this treatment (Non-Radi…

Adultmedicine.medical_specialtyAdolescentmedicine.medical_treatment030204 cardiovascular system & hematologyHaemophiliaHemophilia AGastroenterologyradiosynoviorthesis03 medical and health sciencesYoung Adult0302 clinical medicinehaemarthrosisSynovectomyInternal medicineSynovitisArthropathyElbow JointHemarthrosismedicineHumansIn patientYttrium RadioisotopesGenetics (clinical)Reduction (orthopedic surgery)Retrospective StudiesRadioisotopesHaemophilic arthropathyBleeding episodesSynovitisbusiness.industryShoulder Jointhaemophilic arthropathyHematologyGeneral MedicineMiddle Agedmedicine.diseaseChronic synovitisRheniumTreatment OutcomeDisease ProgressionJoint DiseasesbusinesssynovitisAnkle Joint030215 immunologyHaemophilia : the official journal of the World Federation of Hemophilia
researchProduct

PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multice…

2021

none 38 no BACKGROUND: Natalizumab (NTZ) is an effective treatment for relapsing-remitting multiple sclerosis (RRMS). However, patients and physicians may consider discontinuing NTZ therapy due to safety or efficacy issues. The aim of our study was to evaluate the NTZ discontinuation rate and reasons of discontinuation in a large Italian population of RRMS patients. MATERIALS AND METHODS: The data were extracted from the Italian MS registry in May 2018 and were collected from 51,845 patients in 69 Italian multiple sclerosis centers. MS patients with at least one NTZ infusion in the period between June 1st 2012 to May 15th 2018 were included. Discontinuation rates at each time point were cal…

Adultmedicine.medical_specialtyDiscontinuation rateNeurologyReasons for discontinuationPopulationProgressive MultifocalRelapsing-RemittingSettore MED/26Multiple sclerosis03 medical and health sciences0302 clinical medicineNatalizumabMultiple Sclerosis Relapsing-RemittingLeukoencephalopathyInternal medicineparasitic diseasesmedicineEffective treatmentHumansImmunologic FactorsMultiple sclerosi030212 general & internal medicineeducationRetrospective Studieseducation.field_of_studyDiscontinuation rate; Multiple sclerosis; Natalizumab; Reasons for discontinuation; Adult; Female; Humans; Immunologic Factors; Middle Aged; Natalizumab; Retrospective Studies; Leukoencephalopathy Progressive Multifocal; Multiple Sclerosis; Multiple Sclerosis Relapsing-Remittingbusiness.industryMultiple sclerosisProgressive multifocal leukoencephalopathyNatalizumabLeukoencephalopathy Progressive MultifocalRetrospective cohort studyMiddle Agedmedicine.diseaseDiscontinuationNeurologySettore MED/26 - NeurologiaFemaleNeurology (clinical)business030217 neurology & neurosurgerymedicine.drug
researchProduct

Achievement of treatment targets predicts progression of vascular complications in type 1 diabetes.

2021

Abstract Background and aim To study the association between achievement of guideline-defined treatment targets on HbA1c, low-density lipoproteins (LDL-C), and blood pressure with the progression of diabetic complications in patients with type 1 diabetes (T1D). Methods The study included 355 patients at baseline and 114 patients with follow-up data after 3–5 years. Outcome variables were the progression of diabetic kidney disease, retinopathy, or cardiovascular disease (CVD). We used logistic regression and other machine learning algorithms (MLA) to model the association of achievement of treatment targets and probability of progression of complications. Results Achievement of the target bl…

Adultmedicine.medical_specialtyEndocrinology Diabetes and MetabolismDiseaseLogistic regressionOddsDiabetes ComplicationsMachine LearningEndocrinologyRisk FactorsInternal medicineDiabetes mellitusInternal MedicinemedicineHumansDiabetic NephropathiesGlycated HemoglobinType 1 diabetesbusiness.industryCholesterol LDLMiddle Agedmedicine.diseaseLatviaBlood pressureDiabetes Mellitus Type 1Treatment OutcomeCardiovascular DiseasesHypertensionDisease ProgressionComplicationbusinessRetinopathyFollow-Up StudiesJournal of diabetes and its complications
researchProduct

Pregnancy outcomes in women with advanced HIV infection in Italy

2011

Pregnancy has been associated with a low risk of HIV disease progression. Most pregnancies with HIV currently involve women who have not experienced AIDS-defining events, and are clinically classified as Centers for Disease Control and Prevention (CDC) groups A or B. We evaluated the main maternal outcomes among pregnant women with more advanced HIV disease, defined by CDC-C disease stage. Data from the Italian National Program on Surveillance on Antiretroviral Treatment in Pregnancy were used. A total of 566 HIV-infected mothers, 515 in stage A or B (CDC-AB group) and 51 in stage C (CDC-C group) were evaluated. The two groups had similar baseline characteristics. No differences were found …

Adultmedicine.medical_specialtyGestational AgeHIV InfectionsDiseaseSettore MED/17 - MALATTIE INFETTIVESeverity of Illness IndexYoung AdultAcquired immunodeficiency syndrome (AIDS)ANTIRETROVIRAL THERAPYRisk FactorsPregnancyAntiretroviral Therapy Highly ActiveSeverity of illnessmedicineHumansPregnancy Complications InfectiousYoung adultPregnancyObstetricsbusiness.industryClinical and Epidemiologic ResearchPregnancy OutcomePublic Health Environmental and Occupational HealthHIVGestational ageLiterMiddle AgedViral Loadmedicine.diseaseinfectionCD4 Lymphocyte CountLogistic ModelsInfectious DiseasesAnti-Retroviral AgentsItalyImmunologyHUMAN-IMMUNODEFICIENCY-VIRUSDisease ProgressionFemalebusinessViral load
researchProduct

Robotic Radical Hysterectomy After Concomitant Chemoradiation in Locally Advanced Cervical Cancer: A Prospective Phase II Study

2016

Study Objective To assess the feasibility of total robotic radical surgery (TRRS) in patients with locally advanced cervical cancer (LACC) who receive chemoradiation therapy (CT/RT). Design A prospective (preplanned) study of a nonrandomized controlled trial (Canadian Task Force classification level 2). Setting Catholic University of the Sacred Hearth, Rome, Italy. Patients Between September 2013 and January 2016, a total of 40 patients with LACC (Fédération Internationale de Gynécologie et d'Obstétrique stage IB2–III) were enrolled in the study. Interventions Robotic radical hysterectomy (RRH) plus pelvic and/or aortic lymphadenectomy was attempted within 6 weeks after CT/RT. The feasibili…

Adultmedicine.medical_specialtyLocally advancedPhases of clinical researchUterine Cervical NeoplasmsChemoradiation; Locally advanced cervical cancer; Robotic radical hysterectomyHysterectomy03 medical and health sciences0302 clinical medicinePostoperative ComplicationsRobotic Surgical ProceduresRobotic radical hysterectomymedicineHumansIn patientRadical surgeryRadical HysterectomyChemoradiation; Locally advanced cervical cancer; Robotic radical hysterectomy; Obstetrics and GynecologyAgedCervical cancerLocally advanced cervical cancer030219 obstetrics & reproductive medicinebusiness.industryObstetrics and GynecologyChemoradiotherapy AdjuvantMiddle Agedmedicine.diseaseCombined Modality TherapySurgerySettore MED/40 - GINECOLOGIA E OSTETRICIAChemoradiation030220 oncology & carcinogenesisConcomitantCarcinoma Squamous CellDisease ProgressionFeasibility StudiesLymph Node ExcisionFemaleLaparoscopybusiness
researchProduct

Oxygenation Status of Gynecologic Tumors: What is the Optimal Hemoglobin Level?

2002

Tumor hypoxia has been linked to the development of treatment resistance, tumor progression, and poor prognosis. Since anemia is a major causative factor for the development of hypoxia, the association between blood hemoglobin concentration (cHb) and tumor oxygenation was examined in this study.Pretreatment O(2) tension (pO(2)) measurements were performed in 59 primary carcinomas of the uterine cervix in which a stringent histopathologic examination of the electrode tracks was mandatory in order to exclude measurements in necrotic, stromal or normal cervical tissue. In addition, pO(2) readings in twelve primary cancers and 17 local recurrences of vulvar cancers were included in this study. …

Adultmedicine.medical_specialtyPathologyAnemiaUterine Cervical NeoplasmsCervix UteriGastroenterologyVulvaOxygen ConsumptionInternal medicineCarcinomamedicineHumansRadiology Nuclear Medicine and imagingAgedNeoplasm StagingVulvar NeoplasmsTumor hypoxiabusiness.industryMiddle AgedTumor OxygenationVulvar cancerHypoxia (medical)Prognosismedicine.diseaseCell HypoxiaTreatment OutcomeOncologyTumor progressionCarcinoma Squamous CellHemoglobinometryFemaleHemoglobinemiamedicine.symptombusinessStrahlentherapie und Onkologie
researchProduct

TUR and Adjuvant Intravesical Chemotherapy in T1G3 Bladder Tumors: Recurrence, Progression and Survival in 137 Selected Patients Followed Up to 20 Ye…

2003

Abstract OBJECTIVES: To evaluate a highly selected population of patients affected by T1G3 bladder transitional cell carcinoma (TCCB) treated by transurethral resection (TUR) and adjuvant intravesical chemotherapy. MATERIALS AND METHODS: Between January 1976 and April 1999, 137 patients with T1G3 TCCB were treated by TUR plus intravesical chemotherapy. Particularly, a sequential combination of mitomycin C (MMC) and epirubicin (EPI) was adopted in 91 patients (66.4%). The main exclusion criteria were concomitant or previous Tis, previous T1G3 TCCB, tumor size greater than 3 centimeters and number of tumors more than 3. TUR was repeated if a superficial tumor recurred. Patients went off study…

Adultmedicine.medical_specialtyTime FactorsUrologyPopulationUrologyIntravesical adjuvant chemotherapyDisease-Free SurvivalSettore MED/24 - UrologiaT1G3 bladder cancermedicineAdjuvant therapyHumanseducationSurvival rateAgedNeoplasm StagingAged 80 and overCarcinoma Transitional Celleducation.field_of_studyUrinary bladderBladder cancerbusiness.industryMiddle Agedmedicine.diseaseSurgerySurvival Ratemedicine.anatomical_structureUrinary Bladder NeoplasmsChemotherapy AdjuvantTumor progressionConcomitantDisease ProgressionUrologic Surgical ProceduresNeoplasm Recurrence LocalbusinessConservative treatmentFollow-Up StudiesEpirubicinmedicine.drugEuropean Urology
researchProduct